The U.S. FDA has acquired InnoGI’s tiny-TIMsg system, funded by contract #75F40123P00476, to enhance research on oral drug efficacy, quality, and safety. The system replicates complex GI conditions, providing a more accurate alternative to traditional dissolution methods and emerged as the only solution available on the market perfectly aligning with FDA’s requirements.

InnoGI Technologies teamed up with SimulationsPlus® to combine its advanced TIM Technology with the powerful GastroPlus® software, revolutionizing drug behavior modeling. This collaboration offers next-level modeling solutions, providing more accurate IVIVCs and enhancing PBPK models.

A letter from our CEO, Behzad Mahdavi PhD, MBA, describes the vision and mission of InnoGI technologies to revolutionize drug development using our groundbreaking SurroGUT™ platform, the most realistic model of the human GI tract available today, which makes animal-free drug testing a realistic possibility.